Sanofi (SNYN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sanofi (SNYN) has a cash flow conversion efficiency ratio of 0.048x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (MX$3.44 Billion ≈ $198.26 Million USD) by net assets (MX$71.71 Billion ≈ $4.13 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sanofi - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Sanofi's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sanofi Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sanofi ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Progressive Corp
NYSE:PGR
|
1.138x |
|
BP p.l.c
MX:BPN
|
0.103x |
|
China Merchants Bank Co Ltd
SHG:600036
|
0.030x |
|
Newmont Corporation
AU:NEM
|
0.110x |
|
Banco Bilbao Vizcaya Argentaria SA
MC:BBVA
|
0.278x |
|
Enbridge Inc
TO:ENB
|
0.049x |
|
Capital One Financial Corporation
NYSE:COF
|
0.069x |
|
China Shenhua Energy Co
SHG:601088
|
0.054x |
Annual Cash Flow Conversion Efficiency for Sanofi (2013–2025)
The table below shows the annual cash flow conversion efficiency of Sanofi from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | MX$71.71 Billion ≈ $4.13 Billion |
MX$10.75 Billion ≈ $618.67 Million |
0.150x | +28.53% |
| 2024-12-31 | MX$77.86 Billion ≈ $4.48 Billion |
MX$9.08 Billion ≈ $522.61 Million |
0.117x | -15.46% |
| 2023-12-31 | MX$74.35 Billion ≈ $4.28 Billion |
MX$10.26 Billion ≈ $590.35 Million |
0.138x | -3.65% |
| 2022-12-31 | MX$73.51 Billion ≈ $4.23 Billion |
MX$10.53 Billion ≈ $605.77 Million |
0.143x | -6.06% |
| 2021-12-31 | MX$69.03 Billion ≈ $3.97 Billion |
MX$10.52 Billion ≈ $605.54 Million |
0.152x | +29.75% |
| 2020-12-31 | MX$63.15 Billion ≈ $3.63 Billion |
MX$7.42 Billion ≈ $426.91 Million |
0.117x | -10.00% |
| 2019-12-31 | MX$59.11 Billion ≈ $3.40 Billion |
MX$7.71 Billion ≈ $444.00 Million |
0.131x | +38.91% |
| 2018-12-31 | MX$59.03 Billion ≈ $3.40 Billion |
MX$5.55 Billion ≈ $319.23 Million |
0.094x | -25.82% |
| 2017-12-31 | MX$58.26 Billion ≈ $3.35 Billion |
MX$7.38 Billion ≈ $424.66 Million |
0.127x | -6.72% |
| 2016-12-31 | MX$57.72 Billion ≈ $3.32 Billion |
MX$7.84 Billion ≈ $451.08 Million |
0.136x | -11.39% |
| 2015-12-31 | MX$58.21 Billion ≈ $3.35 Billion |
MX$8.92 Billion ≈ $513.35 Million |
0.153x | +12.12% |
| 2014-12-31 | MX$56.27 Billion ≈ $3.24 Billion |
MX$7.69 Billion ≈ $442.56 Million |
0.137x | +12.09% |
| 2013-12-31 | MX$57.03 Billion ≈ $3.28 Billion |
MX$6.95 Billion ≈ $400.20 Million |
0.122x | -- |
About Sanofi
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines protecting against diphtheria… Read more